诊室实验室对PAD经皮介入医保支付的初步财务影响
基于2006至2013年20% Medicare样本,高诊室实验室(OBL)使用医生治疗的PAD经皮介入患者30天、90天和1年总医保支付显著高于医院对照组。转为OBL的医生支付也增加,主要驱动因素为住院、重复下肢手术和伤口状态。
要点
- 高OBL使用医生患者30天支付高4465美元,1年高27436美元。
- 高OBL使用使1年支付增加49%(95%CI 42%-56%)。
- 转为OBL的医生30天和90天支付增加高于对照。
核心结论
- OBL用于PAD介入显著影响Medicare支付,广泛推广应谨慎。
研究设计与样本
- 回顾性队列研究,使用2006至2013年20% Medicare样本。
- 高OBL用户89名医生治疗887例患者,对照3715名医生治疗54213例患者。
- 转换医生分析纳入292名医生,OBL前3888例,OBL后3246例。
主要发现
- 高OBL用户患者30天支付4465美元,90天8925美元,1年27436美元,均显著高于对照。
- 1年支付增加因素:高OBL使用49%(95%CI 42%-56%),住院127%(95%CI 123%-131%),重复下肢手术41%(95%CI 39%-43%),下肢伤口20%(95%CI 18%-22%)。
- 1年支付减少因素:农村居住8%(95%CI 7%-9%),痴呆5%(95%CI 3%-7%)。
- 转为OBL与30天和90天支付增加相关,且增幅高于对照医生。
临床怎么用
- 关注OBL使用对医保支付的影响,谨慎推广。
- 重点管理住院、重复下肢手术和伤口状态以控制支付。
局限性
- 基于20% Medicare样本,可能影响普适性。
- 观察性设计,无法排除混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Percutaneous interventions for peripheral artery disease (PAD) are transitioning away from hospital-based settings to office-based laboratories (OBLs). Those in favor of OBL use reference lower hospitalization rates and high efficiency; however, critics claim financial incentives may lead to multiple procedures and higher atherectomy use. We sought to determine how Medicare payments are affected by OBL use. METHODS: We identified physicians performing percutaneous interventions for PAD from 2006 to 2013 in a 20% Medicare sample. Physicians performing a majority of interventions at OBLs were classified as high OBL users; control physicians performed interventions at hospital-based settings. The primary outcomes were total Medicare payments at 30 days and 1 year. Generalized log-gamma regression models were used to evaluate factors influencing payments reported as a percentage change and 95% confidence interval (95% CI). A secondary analysis was performed of physicians who transitioned from hospital-based settings to OBLs, "switch physicians." A multivariate model with difference-in-differences regression was used to evaluate the effects of transitioning to OBLs. RESULTS: A total of 89 high OBL users performed percutaneous interventions on 887 patients, and 3715 control physicians treated 54,213 patients during the time period. Payments for patients treated by high OBL users were significantly higher compared with control physicians at 30 days ($4465), 90 days ($8925), and 1 year ($27,436). Major factors increasing payments at 1 year were treatment by a high OBL user (49%; 95% CI, 42%-56%), hospital admissions (127%; 95% CI, 123%-131%), repeated lower extremity procedures (41%; 95% CI, 39%-43%), and lower extremity wound (20%; 95% CI,18%-22%). Factors decreasing payments at 1 year were living in a rural setting (8%; 95% CI, 7%-9%) and dementia (5%; 95% CI, 3%-7%). Analysis of 292 switch physicians identified 3888 patients treated before OBLs (pre-switch) and 3246 after OBLs (post-switch). Transitioning to OBLs was associated with higher payments at 30 days and 90 days, and this increase was higher compared with control physicians. CONCLUSIONS: These findings highlight that OBL use for PAD interventions significantly influences Medicare payments, and its widespread adaptation should be made with caution. The main factors driving payments were hospitalization admissions, repeated lower extremity procedures, and wound status. Further work is needed to evaluate the appropriate use of OBLs to optimize patient outcomes and resource allocations.
引用
- Itoga NK, Baker LC, Mell MW, et al. Initial financial impact of office-based laboratories on Medicare payments for percutaneous interventions for peripheral artery disease. J Vasc Surg. 2020. PMID: 31973948. doi:10.1016/j.jvs.2019.09.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。